Why It Matters
The Cigna Group faces a perfect storm of legislative threats to its core business lines. Bipartisan momentum for Pharmacy Benefit Manager reform directly targets Express Scripts, which controls roughly one-third of the nation’s prescription drug market.
The expiration of Enhanced Advanced Premium Tax Credits threatens to crater ACA marketplace enrollment where Cigna is a major player, while Congressional oversight of Medicare Advantage prior authorization practices jeopardizes cost-management tools the company relies on. Cigna’s $1.37 million Q3 lobbying investment reflects existential stakes: PBM transparency requirements could force radical business model changes, subsidy expiration could slash individual market enrollment, and prior authorization restrictions could upend MA economics.
By the Numbers
The Cigna Group has filed 518 lobbying disclosures since 2003, spending roughly $118.6 million on Capitol Hill advocacy. In Q3 2025, Cigna spent $1.37 million on in-house lobbying, supplementing its core team with external partners like Invariant LLC and Tiber Creek Group Inc.
Cigna’s seven-member in-house team includes strategic 2025 additions. Kara Vlasaty Smith joined after 13 years at competitor UnitedHealth Group and previously served as Staff Director for the Senate HELP Committee’s Aging Subcommittee. Christopher Hartmann brings 14+ years of House Democratic experience, including Chief of Staff role on the House Appropriations Committee. The team’s congressional depth—including Courtney Austin Lawrence’s work for Sen. Bill Cassidy and Rep. Tom Price—reflects Cigna’s need for high-level access as it navigates bipartisan pressure.
The Agenda
The Cigna Group is lobbying on interconnected healthcare priorities in Q3 2025.
The company opposes pharmacy benefit manager reform bills like the PBM Reform Act of 2025 and Pharmacy Benefit Manager Transparency Act targeting spread pricing and rebate opacity that threaten Express Scripts’ business model.
Cigna advocates for extending Enhanced Advanced Premium Tax Credits under the Health Care Affordability Act of 2025, critical for sustaining ACA marketplace enrollment. The company also lobbies on pharmacy provisions within the FY2026 NDAA, protecting its TRICARE pharmacy benefits management amid criticism for reducing participating pharmacies.
Additional priorities include defending Medicare Advantage cost-management tools from congressional restrictions on prior authorization practices and navigating healthcare competition and antitrust concerns.
Broader Context
Congress is intensifying pressure on pharmacy benefit managers in 2025, directly threatening Cigna’s Express Scripts business. Bipartisan legislation targets controversial PBM practices while enhanced ACA tax credits face year-end expiration, potentially destabilizing Cigna’s individual insurance operations.
Cigna’s Medicare Advantage operations face congressional scrutiny over prior authorization practices, with lawmakers examining whether cost-management tools are excessive. Express Scripts continues facing criticism from senators for reducing TRICARE pharmacy networks, forcing military beneficiaries to find new providers.
Between The Lines
The bipartisan PBM reform movement has reached critical mass. House Energy and Commerce Committee hearings highlighted market concentration concerns, while Senate Judiciary investigations condemned PBM tactics. Joint House Ways and Means subcommittee hearings examined prior authorization practices in Medicare Advantage.
On the ACA front, Democrats push for subsidy permanence. Sen. Elizabeth Warren publicly criticized Express Scripts’ TRICARE management over pharmacy network reductions affecting nearly 400,000 beneficiaries.
Competitive Landscape
Major competitors face identical pressures. Elevance Health Inc. lobbies on the same PBM reform bills, while both Elevance and UnitedHealth Group list prior authorization and healthcare competition as key issues. Cigna’s recruitment of Kara Vlasaty Smith from UnitedHealth underscores the competitive nature of healthcare lobbying.
The Bottom Line
The Cigna Group spent $1.37 million in Q3 2025 managing simultaneous legislative threats across four fronts: defending Express Scripts from bipartisan PBM reform, protecting Medicare Advantage practices under congressional scrutiny, advocating for extended ACA premium subsidies, and managing TRICARE criticism. This defensive strategy aims to minimize regulatory restrictions rather than expand market opportunities.
Spot something wrong? Report an issue with this article